<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01570517</url>
  </required_header>
  <id_info>
    <org_study_id>2011-01</org_study_id>
    <nct_id>NCT01570517</nct_id>
  </id_info>
  <brief_title>Feasibility Trial of the DC Devices Interatrial Septal Device (IASD) System</brief_title>
  <official_title>Evaluation of the DC Devices IASD System in the Treatment of Patients With Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corvia Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corvia Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and potential benefits of the interatrial
      septal defect (IASD) System in patients with heart failure with preserved ejection fraction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was a multi-center, non-randomized feasibility evaluation of the IASD System at
      three centers in three countries (Denmark, Australia, and Czech Republic). Relevant ethics
      committee and competent authority approvals were obtained. The study was conducted in
      accordance with the Declaration of Helsinki. The protocol required the treatment of a minimum
      of 5 patients, and allowed up to twenty patients to be enrolled.

      The primary objective of the trial was to evaluate the safety and potential benefits of the
      IASD Device System in the treatment of patients with symptomatic heart failure with preserved
      ejection fraction, despite optimal medical management.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Device Events</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Device implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are implanted with the study device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IASD System</intervention_name>
    <description>Implantation of the DC Devices Inc. IASD System</description>
    <arm_group_label>Device implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of HFpEF

          -  Ejection Fraction of at least 45%

          -  Imaging and hemodynamic evidence of HFpEF

          -  History of exercise intolerance

          -  Symptomatic despite optimal medical management

          -  Signed study specific informed consent

        Exclusion Criteria:

          -  History of thromboembolic events

          -  Significant structural heart disease or coronary artery disease

          -  Contraindicated to study required medication

          -  Right ventricular dysfunction

          -  History of greater than mild restrictive or obstructive lung disease

          -  Life expectancy less than one year for non-cardiovascular reasons

          -  Known or suspected allergy to implant material

          -  Fertile women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Komtebedde, DVM</last_name>
    <role>Study Chair</role>
    <affiliation>DC Devices</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Kaye</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homolka Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czechia</country>
    <country>Denmark</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <results_reference>
    <citation>Søndergaard L, Reddy V, Kaye D, Malek F, Walton A, Mates M, Franzen O, Neuzil P, Ihlemann N, Gustafsson F. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail. 2014 Jul;16(7):796-801. doi: 10.1002/ejhf.111. Epub 2014 Jun 24.</citation>
    <PMID>24961390</PMID>
  </results_reference>
  <results_reference>
    <citation>Malek F, Neuzil P, Gustafsson F, Kaye DM, Walton A, Mates M, Søndergaard L, Ihlemann N, Mariani JA, Reddy V. Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. Int J Cardiol. 2015;187:227-8. doi: 10.1016/j.ijcard.2015.03.198. Epub 2015 Mar 18.</citation>
    <PMID>25841123</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 21, 2012</study_first_submitted>
  <study_first_submitted_qc>April 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

